Revance Therapeutics Inc (RVNC)

[Emannow]

Revance Sales Rep: June 23 2024
Do you see a lot more demand for Daxxify or relatively steady?
Both! “the launch” accounts needed a year to figure it out and realize they cant underdose and split a vial between 3 patients (being cheap) so they are coming around and reordering. New customers are fed up with Allergan and their “new pricing” pressure so calling to get daxxify on their shelves instead. injectors are learning the competitive toxin reps were bad mouthing daxxify and now trying it a year later and they love it. My territory is doing triple YTD. leadership may suck but the product is superior, especially when they don't “water it down” and hyper dilute..